Application of arsenic trioxide-based combined sequential chemotherapy in recurrent resistant and refractory ovarian cancers: a single-center, open phase ii clinical study

HIGHLIGHTS

• who: Yingchao Yang and colleagues from the Department of Obstetrics and Gynecology, Peking University People`s Hospital, No, Xizhimen South Street, Xicheng District, Beijing, China have published the article: Application of Arsenic Trioxide-Based Combined Sequential Chemotherapy in Recurrent Resistant and Refractory Ovarian Cancers: A Single-Center, Open Phase II Clinical Study, in the Journal: Journal of Oncology of 31/08/2022
• what: The aim of this study was to study ATO-based combined sequential chemotherapy in the treatment of refractory and recurrent EOC, to evaluate its efficacy and safety classification of this approach, and . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.